About

bg1 bg2 bg3 bg4

About Uterine Fibroids

Affecting over 25% of women of reproductive age, uterine fibroids are non-cancerous tumours that develop in or on the muscular walls of the uterus and are among the most common reproductive tract tumours in women. In addition to an individual’s genetic predisposition, estrogens are well known to play an important role in the regulation of fibroid growth.

Although uterine fibroids are benign tumours, they can cause debilitating symptoms such as heavy menstrual bleeding (frequently resulting in anaemia and fatigue), pain (including painful periods, abdominal pain, painful intercourse, backache), increased abdominal girth and bloating, urinary frequency or retention, constipation, pregnancy loss, and, in some cases, infertility. These symptoms can also lead to loss of productivity at work, limitations in normal activities of daily living, and social embarrassment.For more information on uterine fibroids visit https://ufperspectives.com

About Gedeon Richter

Gedeon Richter Plc., headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. Richter’s consolidated sales were approximately EUR 1.1 billion(US$ 1.5 billion), while its market capitalization amounted to EUR 2.1 billion (US$ 2.5 billion) in 2014.

The product portfolio of Richter covers almost all-important therapeutic areas, including gynaecology, central nervous system, and cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter’s original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the female healthcare field worldwide. Richter is also active in biosimilar product development.

VISIT GEDEON RICHTER WEBSITE